EPIRUS Biopharmaceuticals Receives $36,000,000 Series B Financing

  • Feed Type
  • Date
    4/17/2014
  • Company Name
    EPIRUS Biopharmaceuticals
  • Mailing Address
    699 Boylston Street 11th Floor Boston, MA 02199 USA
  • Company Description
    The biopharmacuticals industry is approaching an unprecedented biologics patent cliff, with emerging markets forging their own regulatory landscapes. EPIRUS is seizing the opportunity with a new business model that adapts to the changing dynamics and regulations of today’s market conditions.
  • Website
    http://www.epirusbiopharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $36,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Through this transaction, we gain access to additional financial resources as well as clinical trial experience in the rheumatoid arthritis space. Our combined team is committed to expanding patient access to important medications.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy